Steven T. Rosen, MD, from the City of Hope, Duarte, CA, discusses recent developments in BTK inhibitors at the 2017 International Workshop in Non-Hodgkin Lymphoma (iwNHL) in Vancouver, BC, Canada. BTK inhibitors have been shown to be effective in CLL, mantle cell lymphoma, Waldenstrom macroglobulinemia, and MALT lymphomas, and are constantly being developed to reduce toxicity. More is also being learned about their resistance mechanisms, and the benefit of combinations.
BTK inhibitors: toxicity, resistance, and combinations
